BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 18355656)

  • 1. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Kim HS; Ko JK; Park JH; Lee JH; Choi SW; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Park SJ
    J Am Coll Cardiol; 2008 Mar; 51(12):1181-7. PubMed ID: 18355656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ;
    J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Kim HS; Ko JK; Park JH; Lee JH; Choi SW; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Park SJ;
    Am J Cardiol; 2007 Oct; 100(7):1103-8. PubMed ID: 17884371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
    Lee SW; Chun KJ; Park SW; Kim HS; Kim YH; Yun SC; Kim WJ; Lee JY; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Jon S; Cho YH; Lee NH; Kim JH; Park SJ
    Am J Cardiol; 2010 Jan; 105(2):168-73. PubMed ID: 20102913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    Zuliani Mauro MF; Mangione JA; Costa JR; Costa R; Piva E Mattos LA; Staico R; Feres F; Siqueira D; Sousa A; Abizaid A
    J Invasive Cardiol; 2017 Mar; 29(3):76-81. PubMed ID: 28255102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
    Lee SW; Lee JY; Ahn JM; Park DW; Han S; Park YK; Lee WS; Jang JY; Kwon CH; Park GM; Cho YR; Kim WJ; Kang SJ; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2013 Dec; 112(11):1738-44. PubMed ID: 24063835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials).
    Lee SW; Ahn JM; Han S; Park GM; Cho YR; Lee WS; Jang JY; Kwon CH; Lee JY; Kim WJ; Kang SJ; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2013 Nov; 112(9):1328-34. PubMed ID: 23890573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
    Lee SW; Park SW; Yun SC; Kim YH; Park DW; Kim WJ; Lee JY; Lee CW; Hong MK; Kim JJ; Park SJ
    Am Heart J; 2010 Feb; 159(2):284-291.e1. PubMed ID: 20152228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
    Youn YJ; Lee JW; Ahn SG; Lee SH; Choi H; Yu CW; Hong YJ; Kwon HM; Hong MK; Jang Y; Yoon J
    Am Heart J; 2014 Feb; 167(2):241-248.e1. PubMed ID: 24439986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial.
    Suh JW; Lee SP; Park K; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    Int Heart J; 2017 Dec; 58(6):853-860. PubMed ID: 29118299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
    Ahn Y; Jeong MH; Jeong JW; Kim KH; Ahn TH; Kang WC; Park CG; Kim JH; Chae IH; Nam CW; Hur SH; Bae JH; Kim KY; Oh SK
    Circ J; 2008 Jan; 72(1):35-9. PubMed ID: 18159096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: a meta-analysis.
    Chen Z; Qian J; Chen Y; Ma J; Ge J
    J Clin Pharmacol; 2013 May; 53(5):532-9. PubMed ID: 23436428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
    Lee SA; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Kim HS; Kim SH; Choi DJ
    Contemp Clin Trials; 2015 Jul; 43():20-4. PubMed ID: 25891091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
    Sakurai R; Koo BK; Kaneda H; Bonneau HN; Nagai R
    Int J Cardiol; 2013 Sep; 167(5):2250-8. PubMed ID: 22727963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
    Lee SW; Park SW; Hong MK; Kim YH; Lee BK; Song JM; Han KH; Lee CW; Kang DH; Song JK; Kim JJ; Park SJ
    J Am Coll Cardiol; 2005 Nov; 46(10):1833-7. PubMed ID: 16286167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A paclitaxel-eluting stent for the prevention of coronary restenosis.
    Park SJ; Shim WH; Ho DS; Raizner AE; Park SW; Hong MK; Lee CW; Choi D; Jang Y; Lam R; Weissman NJ; Mintz GS
    N Engl J Med; 2003 Apr; 348(16):1537-45. PubMed ID: 12700373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.